Equillium reports q4 loss per share of $0.44

Equillium reports fourth quarter and full-year 2019 financial results and provides business update.q4 loss per share $0.44.q4 earnings per share estimate $-0.39 -- refinitiv ibes data.equillium - maintaining guidance that we anticipate reporting initial data from equate study during second half of 2020.equillium - reiterate guidance that cash on hand is sufficient to fund operations into second half of 2021.equillium - held cash, cash equivalents and short-term investments totaling about $53.1 million at dec 31, 2019.equillium - have paused enrollment in the equip trial for uncontrolled asthma and the equalise trial for lupus nephritis.equillium - reaffirms guidance to report initial data from equate trial in acute gvhd in h2 2020.
EQ Ratings Summary
EQ Quant Ranking